Eos Energy stock falls after Fuzzy Panda issues short report
TAMPA/PHILADELPHIA - Wellgistics Health, Inc. (NASDAQ:WGRX) has entered into a software as a service agreement with DataVault AI, Inc. (NASDAQ:DVLT) to develop blockchain-enabled smart contracts for the prescription drug industry, according to a company press release issued Monday. DataVault AI, currently valued at $645.54M, has shown remarkable momentum with a 117% price return over the past six months, according to InvestingPro data.
The companies are developing a system called PharmacyChain that aims to track prescriptions from manufacturers to patients. The partners expect to finalize a profit-sharing license agreement in the fourth quarter of 2025.
"We have already received significant inbound interest from manufacturers, pharmacists and insurers," said Prashant Patel, President and Interim-CEO of Wellgistics.
Beta testing for PharmacyChain is expected to begin in the first half of 2026. The system will utilize DataVault AI’s Web 3.0 platform and patented technology to enable secure data transfer between pharmaceutical stakeholders.
The companies stated the technology will allow pharmacies to receive and transfer data to help pharmacists make appropriate drug dispensing decisions. The system may eventually incorporate diagnostic and biometric data on an opt-in basis.
Wellgistics connects 6,500 pharmacies and 200 manufacturers through its integrated platform offering wholesale distribution, digital prescription routing, and AI-powered services.
Nathaniel Bradley, President and CEO of DataVault AI, referenced the "$639 billion prescription drug market" as the target for developing new revenue streams through this partnership. While InvestingPro analysis indicates DataVault AI’s aggressive revenue growth forecast of 424% for FY2025, the company’s overall financial health score remains weak at 1.32, with negative EBITDA of -$28.62M in the last twelve months. For deeper insights into DataVault AI’s growth potential and risks, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
The companies indicated the technology would aim to align prescribed medicines with wellness regimens based on personal health data from wearable devices. With DataVault AI trading near its 52-week high, investors seeking to evaluate similar high-growth technology companies can access detailed financial metrics and analysis through InvestingPro’s extensive database of over 1,400 US stocks.
In other recent news, Datavault AI Inc. has signed a letter of intent to acquire NYIAX Inc., a technology company with operations in the U.S., Europe, and Dubai. This acquisition, expected to close in the first quarter of 2026, is still subject to Nasdaq approval and a definitive agreement with customary closing conditions. Datavault AI also announced a strategic partnership with Max International AG to establish a Switzerland-based digital exchange for Real World Assets, which will focus on tokenizing physical assets such as commodities and rights related to name, image, and likeness. The collaboration aims to leverage Switzerland’s regulatory framework to address key institutional adoption barriers. Additionally, Datavault AI regained compliance with Nasdaq’s minimum bid price requirement, maintaining a closing bid price above $1.00 per share for ten consecutive trading days. Furthermore, the company has appointed former Navy SEAL Pete Scobell as Vice President of Global Security to oversee global security operations and risk management. These developments highlight Datavault AI’s continued expansion and strategic initiatives in the digital asset space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.